Circulatory 25(OH)D and 1,25(OH) 2 D as differential biomarkers between multiple system atrophy and Parkinson's disease patients.
| Autor: | Ogura H; Department of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan., Hatip-Al-Khatib I; Department of Medical Pharmacology, Faculty of Medicine, Pamukkale University, Denizli, Turkey., Suenaga M; Department of Medical Pharmacology, Faculty of Pharmaceutical Sciences, Tokushima-Bunri University, Tokushima, Japan., Hatip FB; Department of Medical Pharmacology, Faculty of Medicine, Pamukkale University, Denizli, Turkey., Mishima T; Department of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan., Fujioka S; Department of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan., Ouma S; Department of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan., Matsunaga Y; Department of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan., Tsuboi Y; Department of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | ENeurologicalSci [eNeurologicalSci] 2021 Sep 23; Vol. 25, pp. 100369. Date of Electronic Publication: 2021 Sep 23 (Print Publication: 2021). |
| DOI: | 10.1016/j.ensci.2021.100369 |
| Abstrakt: | Background and Purpose: There is sufficient evidence to support vitamin D's noncalcemic effects and the role of vitamin D deficiency in the development of a wide range of neurological disorders. This study aimed to evaluate whether serum 25(OH)D and 1,25(OH) 2 D could be used as biomarkers to differentiate between healthy subjects (HS), multiple system atrophy (MSA) and Parkinson's disease (PD) patients of both genders. Methods: A total of 107 subjects were included in this study, divided into three groups: 1- HS ( n = 61), 2- MSA patients ( n = 19), and 3- PD patients ( n = 27). The patients were assessed using UMSARS II, UPDRS III, H&Y, MMSE and MoCA rating scales. The levels of 25(OH)D and 1,25(OH) 2 D in serum were determined using the radioimmunoassay technique. Results: The levels of 25(OH)D and 1,25(OH) 2 D in HS were 26.85 +/- 7.62 ng/mL and 53.63 +/- 13.66 pg/mL respectively. 25(OH)D levels were lower in both MSA and PD by 61% and 50%, respectively ( P = 0.0001 vs. HS). 1,25(OH) 2 D levels were lower in MSA by 29%( P = 0.001 vs HS). There was a correlation between 25(OH)D and 1,25(OH) 2 D in MSA and PD, but not in HS. 1,25(OH) 2 D regressed with MMSE (β = 0.476, P = 0.04, R 2 = 0.226) in MSA, and with UPDRS III (β = -0.432, P = 0.024, R 2 = 0.187) and MoCA (β = 0.582, P = 0.005,R 2 = 0.279) in PD. 25(OH)D displayed considerable differentiative strength between HS and MSA (Wald = 17.123, OR = 0.586, P = 0.0001; AUC = 0.982, sensitivity and Youden index = 0.882, P = 0.0001) and PD (Wald = 18.552, OR = 0.700, P = 0.0001; AUC = 0.943, sensitivity = 0.889, YI = 0.791, P = 0.0001). 1,25(OH) 2 D distinguished MSA from PD (Wald 16.178, OR = 1.117, P = 0.0001; AUC = 0.868, sensitivity = 0.926, Youden index =0.632, P = 0.0001). H&Y exhibited the highest sensitivity, AUC, and significant distinguishing power between MSA and PD. Conclusions: Serum 25(OH)D and 1,25(OH) 2 D could be useful biomarkers for MSA and PD. 25(OH)D and H&Y provided the highest sensitivity and group classification characteristics. (© 2021 The Author(s).) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|